With combination antiretroviral therapy (cART) in HIV-infected women, mother-to-child transmission rates declined to less than 1%. For post-natal infant prophylaxis, in situations of low risk of perinatal HIV transmission, high income countries use zidovudine (ZDV), whereas low income countries use either nevirapine (NVP) or ZDV. Given the low transmission risk and the concerns about the toxicities of ZDV in newborns, French national guidelines recommend since 2015 the use of NVP as an alternative to ZDV for post-natal prophylaxis in full term babies born to HIV1-infected mothers with suppressed viral load and no history of NVP resistance. We compared hematological outcomes between ZDV-exposed and NVP-exposed infants.
In the French prospective national Perinatal Cohort Study, we compared hematological outcomes (blood cell counts and differentials) at birth, 1 and 3 months among the infants born in 2016-2017 , at >=37weeks gestation. We included only mothers treated with cART without ZDV, to exclude a potential impact of maternal treatment on infant outcomes. ZDV was prescribed for 4 weeks, NVP for 2 weeks; mothers did not breastfeed.
137 infants were exposed to NVP and 251 to ZDV. None became infected.68% of mothers were born in sub-Saharan Africa (79.4% in NVP group, 62.9% in ZDV group) .Median hemoglobin levels were respectively 17.4 g/dL vs 17.0 at birth (p=0.49),11.7 vs 11 g/dL at 1month (p=0.003) and 11.4 vs 11.2 g/dL at 3 months(p=0.02).Anemia grade >=2 was observed in 0.8% vs 1.7 % of infants at birth (p=0.66), 1.2% vs 9.4% at 1 month (p=0.014), 3.6% vs 7.3% at 3 months(p=0.40). Median neutrophil counts were similar, grade >=2 neutropenia was found in 4.2% vs 2.7% infants at birth(p=0.53),15.9% vs 13.1% at 1 month(p=0.56), and 12.2 vs 13.4% at 3 months(p=0.84). No difference was found in platelets counts.
In this population of HIV-exposed uninfected infants, post-natal prophylaxis with NVP, compared to ZDV was associated with higher hemoglobin levels at 1 and 3 months and a 9-fold lower incidence of anemia at 1 month of age. These findings support the use of nevirapine as a first choice for single drug post-natal prophylaxis in low risk situations.